Galectin Therapeutics (GALT) Reports Q2 Loss of $0.21
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.